SBPH News

Spring Bank Pharmaceuticals, which is developing small molecule therapies for hepatitis B and viral diseases, raised $11 million by offering 0.9 million shares at $12, the low end of the range of $12 to $14. Spring Bank Pharmaceuticals plans to list on the Nasdaq under the symbol SBPH. Dawson James acted as a lead manager on the deal....read more

Of the four biotech IPOs that were scheduled to price this week, only two priced successfully. These were the first two biotech IPOs in almost a month, both of which had heavy insider buying. ...read more

After seven IPOs in a row outside the healthcare sector, four biotechs will attempt to price their IPOs in the week ahead, all with insider support. Looking more broadly, the next two weeks could see an increased number of launches if companies in the pipeline wish to complete their deals before the Memorial Day...read more

Spring Bank Pharmaceuticals, which is developing small molecule therapies for hepatitis B and viral diseases, lowered the proposed deal size for its previously postponed IPO on Wednesday. The Hopkinton, MA-based company now plans to raise $15 million by offering 1.2 million shares at a price range of $12 to $14. Insiders intend to purchase $8 million worth of shares in the...read more